News
Starting Strong: Wanbangde Group and Its Subsidiaries Garner Three Prestigious Awards
Date:
28 Mar,2022
On February 8, the Taizhou Private Economy Development and Business Environment Optimization Conference was held. During the event, the list of Taizhou's Top 100 Taxpayers for 2021 and the Top 50 Tax-Performing Private Enterprises in Taizhou were announced. Wanbangde Group also achieved impressive results.
Honors (1)
"Top 100 Taxpayers in Taizhou for 2021"
Wanbangde Group ranks 49th
Honors (II)
"Top 50 Tax-Paying Private Enterprises in Taizhou for 2021"
Wanbangde Group ranks 41st.
Honour (III)
"Top 10 Industrial Enterprises in Wenling City for 2021"
Wanbangde Pharmaceutical Group ranks 4th.
It is reported that the ranking list was compiled by the Municipal Transformation and Promotion Office, which collaborated with relevant departments—including industry and information technology, finance, taxation, science and technology, and emergency management—to conduct a comprehensive assessment of local industrial enterprises based on key metrics such as 2021 annual main business revenue, tax contributions, R&D investment, profits, and safety production performance.
Founded in 1978, Wanbangde Group has grown over more than 40 years into a large private-sector conglomerate whose core businesses include pharmaceuticals, medical devices, aluminum profiles, and bearings & steel balls. The group boasts subsidiaries across Africa as well as numerous provinces and cities throughout China, with its publicly listed company being Wanbangde Pharmaceutical Holdings Group Co., Ltd. (Stock symbol 002082) , the group's registered trademark has been recognized as a China Well-Known Trademark.
Wanbangde Pharmaceutical Group, a subsidiary under our umbrella, is the core enterprise of Wanbangde Pharmaceutical Holdings Group Co., Ltd., a publicly listed company. Founded in 1970, it is a high-tech enterprise dedicated to the research, development, production, and sales of modern Chinese medicines, chemical APIs, and pharmaceutical preparations. Its product portfolio spans multiple therapeutic areas, including cardiovascular and cerebrovascular diseases, neurological disorders, respiratory conditions, and digestive system ailments. Notably, the company boasts two flagship products with full intellectual property rights: the world’s first-ever huperzine A API and injection, as well as Yinxingye Dripping Pills—China’s exclusive protected traditional Chinese medicine formulation.
Wanbangde Group has always adhered to the business philosophy of "Pioneering Innovation, Caring for Life." While steadily advancing its sustainable growth, the company remains true to its original aspirations, diligently fulfilling its tax obligations and proactively upholding tax compliance. This prestigious recognition not only affirms the company’s long-standing commitment to voluntarily embracing social responsibility but also underscores its efforts in building a positive corporate image and achieving high-quality development.
In the future, Wanbangde Group will continue to forge ahead with determination, striving toward the goal of "recreating new glory for the private economy," while demonstrating the unwavering commitment and steadfast resolve that private enterprises should embody in the new era. We will actively serve as builders, guardians, and advocates of Taizhou's vibrant business environment.
Related Recommendations
2021/02/07